Abstract
Transcatheter aortic valve replacement (TAVR) has become standard therapy for patients with severe aortic stenosis who are deemed at least intermediate risk for surgical valve replacement. Over the past decade, several technological advances have taken place to improve the quality and safety of these devices. The current commercially available valves are broadly grouped into balloon expandable and self-expandable valves. The latest iteration of the self-expandable valve is Medtronic’s repositionable valve known as the Evolut PRO system. In this review, we highlight the evidence behind the use of TAVR, improvement in devices over previous generations, clinical evidence behind the CoreValve Evolut PRO system, and the future of TAVR.
Original language | English (US) |
---|---|
Pages (from-to) | 183-192 |
Number of pages | 10 |
Journal | Cardiology and Therapy |
Volume | 6 |
Issue number | 2 |
DOIs | |
State | Published - Dec 1 2017 |
Externally published | Yes |
Keywords
- Aortic stenosis
- Balloon-expanding valve
- Evolut PRO
- Evolut R
- Medtronic CoreValve
- Self-expanding valve
- Surgical aortic valve replacement
- Transcatheter aortic valve replacement
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine